Indivior Pharmaceuticals, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Superinvestors holding INDV, Q2 2026
1 superinvestor reports holding Indivior Pharmaceuticals, Inc. on Form 13F, worth $251.4M in total. Weight is Indivior Pharmaceuticals, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Oaktree CapitalHoward Marks | 4.7% | 6,127,212 | $251.4M | Reduced−12.3% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of INDV each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−12.3%)
Q1 2026
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−1.8%)
- Sold out
- Soros Fund Management
Q4 2025
2 superinvestors holding at quarter end
- Reduced
- Oaktree Capital (−97.2%), Soros Fund Management (−14.7%)
Q3 2025
2 superinvestors holding at quarter end
- New
- Soros Fund Management
- Added
- Oaktree Capital (+2,241.6%)
Q1 2025
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+26.1%)
Q4 2024
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−8.3%)
Q3 2024
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+111.9%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+34.1%)
Q1 2024
1 superinvestor holding at quarter end